Next Article in Journal / Special Issue
Cross-Reactive and Lineage-Specific Single Domain Antibodies against Influenza B Hemagglutinin
Previous Article in Journal / Special Issue
Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery
Open AccessReview

Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer

Aix Marseille University, CNRS, INSERM, Institute Paoli-Calmettes, CRCM, 13009 Marseille, France
*
Author to whom correspondence should be addressed.
Antibodies 2019, 8(1), 13; https://doi.org/10.3390/antib8010013
Received: 18 December 2018 / Revised: 16 January 2019 / Accepted: 17 January 2019 / Published: 21 January 2019
(This article belongs to the Special Issue Nanobody)
In the last decade, cancer immunotherapies have produced impressive therapeutic results. However, the potency of immunotherapy is tightly linked to immune cell infiltration within the tumor and varies from patient to patient. Thus, it is becoming increasingly important to monitor and modulate the tumor immune infiltrate for an efficient diagnosis and therapy. Various bispecific approaches are being developed to favor immune cell infiltration through specific tumor targeting. The discovery of antibodies devoid of light chains in camelids has spurred the development of single domain antibodies (also called VHH or nanobody), allowing for an increased diversity of multispecific and/or multivalent formats of relatively small sizes endowed with high tissue penetration. The small size of nanobodies is also an asset leading to high contrasts for non-invasive imaging. The approval of the first therapeutic nanobody directed against the von Willebrand factor for the treatment of acquired thrombotic thrombocypenic purpura (Caplacizumab, Ablynx), is expected to bolster the rise of these innovative molecules. In this review, we discuss the latest advances in the development of nanobodies and nanobody-derived molecules for use in cancer immunotherapy and immunoimaging. View Full-Text
Keywords: Nanobody; Single Domain Antibody; Cancer; Immunotherapy; Imaging Nanobody; Single Domain Antibody; Cancer; Immunotherapy; Imaging
Show Figures

Figure 1

MDPI and ACS Style

Chanier, T.; Chames, P. Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer. Antibodies 2019, 8, 13.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop